CB2 Insights (CSE:CBII) CEO Prad Sekar talked about taking the company public on the Canadian Securities Exchange with Yahoo Finance’s Sibile Marcellus and Charreah Jackson.
CB2 Insights (CSE:CBII) CEO Prad Sekar talked about taking the company public on the Canadian Securities Exchange with Zack Guzman and Yahoo Finance’s Sibile Marcellus and Charreah Jackson. CB2 Insights is an established, data-focused cannabis solution provider. The company’s mission is to mainstream medical cannabis into traditional healthcare by providing the industry with real-world evidence driven through its clinical operations.
In the interview, Sekar discussed how medications get introduced to the traditional medical healthcare system. Drug developers are required to provide evidence and information before it passes through “gatekeepers” to the market. If you don’t have the information that physicians and clinicians require or that information isn’t presented in a way that they’re used to, then your drug won’t go to market. As a result, CB2 Insights collects clinically-led, evidence-based data to help cannabis companies bring an advanced level of knowledge to the industry in terms of qualification, dosing and efficacy despite the lack of cannabis-based clinical trials. Sekar believes that this approach to medical cannabis can lead to its adoption into a more traditional healthcare setting.
CB2 Insights also run medical clinics that provide services and collect data from approximately 60,000 patients annually. To date, the company has generated C$10 million in revenue from its clinics. At the clinics, CB2 Insights collects data on the interactions between patients and physicians, which allows the company to standardize the information being looked at when treating patients, their outcomes and efficacy, Pekar explained. The clinics are addressing issues of patient-led, self-reported data, which can be difficult to validate. The clinics also act as a center of excellence for both patients and physicians.
To watch the full video, click here.